July 2, 2024Journal of Travel Medicine13 citations

Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine

VBVera Buerger GMGerald Maurer KKKarin Kosulin

Key Points

Key points are not available for this paper at this time.

Abstract

Chikungunya is a serious and debilitating viral infection with a significant disease burden. VLA1553 (IXCHIQ®) is a live-attenuated vaccine licensed for active immunization for prevention of disease caused by chikungunya virus (CHIKV).

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Buerger et al. (Tue,) studied this question.

synapsesocial.com/papers/68e61a51b6db6435875ac5b8 https://doi.org/https://doi.org/10.1093/jtm/taae084

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Trends in imported infections among migrants and travellers to Spain: a decade of analysis through the +Redivi network (2012–2022)2024 · 13 citations
2A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults2023 · 38 citations
3Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial2023 · 236 citations
4Dengue, chikungunya and Zika in GeoSentinel surveillance of international travellers: a literature review from 1995 to 20202020 · 57 citations
5Chikungunya infection: self-reported rheumatic morbidity and impaired quality of life persist 6 years later2015 · 106 citations

Demander à l'IA

Bookmark

View Full Paper